-
New drug for Acinetobacter infections shows promise in phase 3 trial
20 Oct 2021 00:22 GMT
Pharmaceutical company Entasis … well-controlled clinical trial of carbapenem-resistant Acinetobacter-infected … to current treatment options for this high-medical-need and … Drug Administration (FDA), a designation that aims to spur development of new antibiotics …
-
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
19 Oct 2021 12:40 GMT
… mortality in patients with carbapenem-resistant Acinetobacter, demonstrating … ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: … application for the treatment of mild-to- … Biotechnology (NASDAQ: PBYI) to conduct a Phase 2 clinical trial …
-
Entasis Shares Rally On Positive Data From Drug-Resistant Bacterial Infection Candidate
19 Oct 2021 11:42 GMT
… its Phase 3 ATTACK trial of sulbactam-durlobactam ( … polymyxin E) is an antibiotic medication used as a last resort … mortality in patients with carbapenem-resistant Acinetobacter infections and … population were comparable between treatment groups.
The company is …
-
Global Antibiotics Markets Report 2021: Market Size is Expected to Reach $57.99 Billion by 2028 - Growing Collaborations for Development of Antibiotics
15 Oct 2021 12:54 GMT
… Drug Application (sNDA) from the U.S. FDA … to antibiotic therapies that address unmet medical needs. … antibiotics as well as some newly developed drugs, such as tetracycline, carbapenem … Melinta Therapeutics Teva Pharmaceutical Industries Ltd. Nabriva …
-
Oral Antibiotics Market is expected to play a significant role in bringing a $23,306.10 Bn boost to the global economy
14 Oct 2021 12:33 GMT
… -Spectrum Antibiotic, Mid/narrow-spectrum Antibiotic), Drug Type … the treatment and control of pathogens. The medications … types of antibiotics such as penicillin, cephalosporin, carbapenem, and … losses. However, pharmaceutical companies have a …
-
Study highlights impact of antibiotic resistance on older Americans
07 Oct 2021 22:16 GMT
… , vancomycin-resistant Enterococcus, carbapenem-resistant Enterobacteriaceae (CRE), and carbapenem-resistant Acinetobacter baumannii … antibiotic-resistant infections.
For example, Pew recommends that the Center for Medicare …
-
OpGen Receives FDA Clearance for Acuitas(R) AMR Gene Panel
04 Oct 2021 11:55 GMT
… and supports appropriate antibiotic treatment decisions in this indication … select drugs in 9 classes of antibiotics, including aminoglycosides, carbapenems, … is the first FDA cleared molecular diagnostic … of Pathology and Laboratory Medicine, and Director of …
-
European Antibiotics Market to Generate $13,529.8 Million by 2027 | Growth & Key Business Strategies
27 Sep 2021 07:13 GMT
… , “European Antibiotics Market by Drug Class, Drug Origin, Spectrum … clinical trials, further supplements the European antibioticsmarket growth. … carbapenems, tigecycline (against MRSA) and linezolid.Other antibiotic therapeutics proposed for the treatment …
-
Carbapenem-Resistant Enterobacteriaceae Infection Market Insights and Market Forecast 2030
25 Sep 2021 02:39 GMT
… current medical therapies and diagnoses available in the Carbapenem-resistant … use of non-antibiotic drugs for the treatment of multidrug-resistant … disadvantage of clinical trials and patent rights remains.
Carbapenem-resistant Enterobacteriaceae …
-
Carbapenem-resistant Enterobacteriaceae Testing Market to Remain Lucrative during 2021-2031 Growing Number of Healthcare Facilities to Boost Market Demand
20 Sep 2021 21:47 GMT
… use of several antibiotics and rise in use of medical devices in … behind increasing demand of Carbapenem-resistant Enterobacteriaceae Testing .Carbapenem-resistant Enterobacteriaceae Testing … pandemic as well as regular doctor visits.
About Fact.MR
Market …
About
© 1995-2021